In NASH patients, increased levels of circulating lipopolysaccharide (LPS) are thought to originate from disturbed gut microbiome25, which stimulate hepatocytes and KCs to trigger inflammation and profibrotic processes1,25. The gene discussed is TBCE; the disease is metabolic dysfunction-associated steatohepatitis.